FDA advisers to assess risks and benefits of Novavax’s Covid-19 vaccine
Based on data included in an agency briefing paper released Friday, an FDA review found that the vaccine’s overall efficacy was 90.4% against mild, moderate, or severe Covid-19 for a period of 2.5 months after the end of the two-dose primary series. The paper notes that, in a primary analysis, vaccine effectiveness fell to 78.6% … [Read more…]